We follow industry news and trends so you can stay ahead of the game. Subscribe to receive emails regarding policies and findings that impact you and your business.

Already a subscriber and want to update your preferences? Click here.

BACK TO NEWS

AUG 21 2019

Corporate Team Assists Sonnet BioTherapeutics in Acquisition Agreement with Relief Therapeutics Holding SA

Buchanan's Corporate team of Rajiv Khanna, Shareholder and Daniel Richey, Associate, worked with client Sonnet Bio Therapeutics, an oncology-focused biotechnology company developing innovative targeted biologic drugs, to complete Sonnet's acquisition agreement with Relief Therapeutics Holding SA (SIX: RLF) to develop atexakin alfa through the acquisition of its subsidiary, Relief Therapeutics SA, via a share exchange transaction. Read Sonnet's news release for more information.